Table 3.

Comparison of absolute and relative risk of CIN2+ based on Aptima HPV on Tigris and cobas HPV on SurePath specimens.

HPV assay	CIN2+/Test positive	% Absolute risk of CIN2+ in test positive (95% CI)	CIN2+/ test negative	% Absolute risk of CIN2+ in test negative (95% CI)	Relative risk of CIN2+(95% CI)
Aptima	135/623	21.7 (18.6–25.1)	13/728	1.8 (1.0–2.9)	12.1 (6.9–21.1)
Cobas HPV	139/684	20.3 (17.5–23.5)	9/667	1.3 (0.7–2.4)	15.0 (7.7–29.1)

CIN 2+=High grade cervical intraepithelial neoplasia grade 2 or worse.